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Severity of disease and mortality for hospitalized patients with
community-acquired viral pneumonia compared to patients with
community-acquired bacterial pneumonia
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Abstract
Background: There exists a large body of literature to help identify, diagnose, treat, and manage
community-acquired pneumonia (CAP). Despite this, there is little data that directly compares the
clinical syndromes and complications of pure bacterial pneumonia to pure viral pneumonia. Our study
compares the clinical presentation, morbidity and mortality of viral vs. bacterial etiologies of CAP.
Methods: This was a secondary data analysis of the Community-Acquired Pneumonia Organization
(CAPO) international study database. Data was collected concerning patient demographics, physical
examination findings, laboratory findings, radiological findings, severity of illness, and clinical
outcomes and stratified according to the two study groups, CAVP and CABP. A microbiological
diagnosis of CABP was based on the isolation of a bacterium from a respiratory sample, blood culture
and/or identification of a urinary antigen for Streptococcus or Legionella; microbiological diagnosis
of CAVP was based on polymerase chain reaction or antigen detection from respiratory samples.
Results: Our study included 1,913 patients. Of these, 286 (15.0%) had viral infection, while 1,627
(85.0%) had CAVP. We found that bacterial CAP patients are older, more frequently male, and suffer
from a higher proportion of comorbidities when compared to viral CAP patients. Comparison of
physical exam findings and laboratory values failed to find a clinically significant difference between
bacterial and viral CAP patients. When comparing severity of illness, bacterial CAP patients had
greater frequency of PSI ≥ class IV; however, viral CAP patients more frequently needed ICU
admission, ventilator support, vasopressor support, and had higher rate of in hospital mortality.
Conclusions: Our study confirms the extreme difficulty differentiating CABP from CAVP using
demographics, physical exam, or x-ray findings. We found no major clinical or laboratory findings
distinguishing CABP from CAVP. The increased severity of illness of CAVP compared to bacterial
etiologies shows that PSI scores may not be an accurate indicator of severity of disease. More
studies are needed to identify the best process of care for patients with CAP, including the potential
benefits of routine respiratory viral panel testing and empiric antiviral therapy.
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Introduction
Pneumonia is an extremely common, yet exceedingly dangerous
condition that makes up 423,000 emergency room visits and is
the 8th leading cause of death in the United States, according to
the CDC [1]. Inpatient community-acquired pneumonia (CAP)
treatment is often empiric and laboratory testing may not result
in a definite organism [2]. It has been demonstrated that the
microbial etiology of roughly 30%-60% of CAPs treated in the
inpatient setting remains unidentified [3-6]. Of those admitted
to the hospital, 10-20% of patients are admitted to the ICU [7].
While imaging and prognosticating tools like the CURB-65 and
Pneumonia Severity Index assist in the diagnosis and severity
assessment of pneumonia, distinguishing between viral and
bacterial pneumonia remains a challenge [8].
Bacterial pneumonia is a major cause of pathogen identified
CAP. For example, Streptococcus pneumoniae is the most
common cause of bacterial pneumonia, causing significant
morbidity and mortality [7]. Tools like procalcitonin levels are
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helpful in the diagnosis and management of bacterial
pneumonia [9]. On the other hand, viral pneumonia, a
significant contributor to the prevalence of CAP, is identified
by polymerase chain reaction (PCR) in more than 25% of
cases using nasopharyngeal swabs and up to 40% when using
lower respiratory tract samples [10]. Tools like rapid antigen
testing and real time PCR assist in the diagnosis of several viral
pneumonias [11]. Furthermore, morbidity and mortality of
bacterial pneumonia after a preceding viral infection increases
[12].
There is a large body of literature to help physicians identify,
diagnose, treat, and manage CAP. Despite this, there is little data
that directly compares the clinical syndromes and complications
of bacterial pneumonia to viral pneumonia. Our study aims to
compare the clinical presentation, morbidity and mortality of
purely viral to purely bacterial etiologies of CAP.
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Methods

Table 2 Most common pathogens isolated in CABP

Study Design
This was a secondary data analysis of the Community-Acquired
Pneumonia Organization (CAPO) international study database.
This multinational database is coordinated by the University of
Louisville School of Medicine, Department of Medicine, Division
of Infectious Diseases. Investigators from 130 hospitals across
30 countries perform data collection designed by the University
of Louisville. Data is electronically transferred and validated by
research associates at the University of Louisville [13].
Subjects
Patients were eligible for inclusion in analysis if they were
hospitalized with CAP and a microbiological diagnosis of a viral
or bacterial infection was established. Patients were enrolled
from 2001 to 2017 and categorized into two groups: those
with confirmed bacterial infection and those with confirmed
viral infection. Patients without an identified bacterial or viral
organism were excluded from the study. Additionally, patients
with any coinfection were excluded.
Study Definitions
Community-acquired pneumonia (CAP):
A patient was defined as having CAP when the following 3
criteria were met: 1) presence of a new pulmonary infiltrate on
chest radiograph and/or chest computed tomography scan at the
time of hospitalization, defined by a board-certified radiologist’s
reading; 2) at least 1 of the following: a) new cough or increased
cough or sputum production, b) fever >37.8°C (100.0°F) or
hypothermia <35.6°C (96.0°F), c) changes in leukocyte count
(leukocytosis: >11000 cells/μL; left shift: >10% band forms/mL;
or leukopenia: <4000 cells/μL); and 3) no alternative diagnosis
at the time of hospital discharge that justified the presence of
criteria 1 and 2 [14].
Hospitalization with community-acquired bacterial
pneumonia (CABP) vs. community-acquired viral
pneumonia (CAVP):
A microbiological diagnosis of CABP was based on the isolation
of a bacterium from a respiratory sample, blood culture and/
or identification of a urinary antigen for Streptococcus or
Legionella; microbiological diagnosis of CAVP was based on
polymerase chain reaction or antigen detection from respiratory
samples.
Coinfection:
A patient was defined as having coinfection if more than one
microorganism was identified. All patients with coinfections
were excluded from analysis.
Table 1 Most common pathogens isolated in CAVP

Pathogen
Influenza H1N1
Influenza H2N2
Rhinovirus
Respiratory Syncytial Viral (A,B)
Parainfluenza Virus (1,2,3)
Adenovirus
Respiratory Syncytial Virus B
Influenza B
Coronavirus NL63

n (%)
250 (87)
11 (4)
8 (3)
5 (2)
5 (2)
4 (1)
1 (0)
1 (0)
1 (0)

Pathogen
Streptococcus pneumoniae
Haemophilus influenzae
MSSA
Legionella spp.
MRSA
Pseudomonas aeruginosa
Mycobacterium tuberculosis
Mycoplasma pneumoniae
Klebsiella pneumoniae
Escherichia coli
Moraxella catarrhalis
Chlamydia pneumoniae
Acinetobacter spp.
Nontuberculous mycobacteria
Proteus spp.
Enterobacter spp.
Streptococcus pyogenes
Pseudomonas pseudomallei
Other

n (%)
858 (53)
115 (7)
99 (6)
95 (6)
79 (5)
72 (4)
61 (4)
56 (3)
50 (3)
35 (2)
34 (2)
18 (1)
10 (1)
8 (0)
8 (0)
7 (0)
6 (0)
4 (0)
12 (1)

Measurements
Data was collected concerning patient demographics, physical
examination findings, laboratory findings, radiological findings,
severity of illness, and clinical outcomes and stratified according
to the two study groups, CAVP and CABP.
Statistical Analysis
Descriptive statistics were performed, with frequencies with
percentages as well as medians with interquartile ranges
reported for categorical and continuous variables, respectively.
Chi-squared tests and Mann-Whitney U-tests were performed
to compare categorical and continuous variables. P-values of
less than 0.05 were considered statistically significant. R v 3.4.3
was used for all analyses [15].

Results
Our study included 1913 patients. Of these, 286 (15.0%) had
CAVP, while 1,627 (85.0%) had CABP. The most common
organisms identified for patients CAVP and CABP depicted in
Tables 1 and 2, respectively.
1.
Patient Demographics
Patients with CABP were older (63 [IQR: 31] vs. 48 [IQR: 28]
years; P < 0.001) and were more frequently male (64% vs
51%; P <0.001) than patients with CAVP. A higher proportion
of co-morbidities, including chronic obstructive pulmonary
disease (COPD), congestive heart failure (CHF), Human
Immunodeficiency Virus (HIV), stroke, and neoplastic diseases
were also more commonly found in patients with CABP in
comparison to those with CAVP.
2. Physical Examination Findings
Comparison between vitals measurements are shown in
Table 3. While many variables were statistically significant,
the differences between the CABP and CAVP groups were not
considered clinically significant.
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Table 3 Patient demographics, physical examination findings, laboratory
findings, and radiological findings

Variable
Total study population, n
Demographics

Male sex, n (%)
Age, Median(IQR)*
Chronic obstructive pulmonary
disease
Diabetes mellitus
Current smoker
Congestive heart failure
HIV disease
Stroke
Neoplastic disease
Renal disease
Chronic renal failure
Home oxygen
Physical Examination Findings
Systolic blood pressure (mmHg)
Heart rate (Beats/Minute)
Diastolic blood pressure (mmHg)
Temperature (Degrees Celsius)
Respiratory rate (Breaths/Minute)
Laboratory Findings
Serum sodium (mEq/L)
Serum glucose (mg/dl)
Hematocrit (percent)
Blood urea nitrogen (mg/dL)
Serum bicarbonate (mEq/L)
Serum procalcitonin (µg/L)
Radiological Findings
Diffuse Bilateral, n (%)
Diffuse Unilateral, n (%)
Multilobar Infiltrate, n (%)
*IQR: Interquartile range

CABP
1627

CAVP
286

P-value

1033 (64) 145 (51) <0.001
63 (31)
48 (28) <0.001
364 (22)

41 (14)

0.002

282 (17)
275 (17)
227 (14)
200 (12)
162 (10)
160 (10)
156 (10)
130 (8)
30 (4)

43 (15) 0.393
58 (20) 0.176
27 (9) 0.038
8 (3) <0.001
8 (3) <0.001
12 (4) 0.002
21 (7) 0.268
22 (8) >0.999
4 (1)
0.032
PMedian (IQR)
value
119 (33) 120 (34) 0.01
104 (31) 100 (28) 0.026
70 (20) 72.5 (23) <0.001
37.8 (1.9) 37.8 (1.7) 0.073
24 (8)
26 (12) <0.001
PMedian (IQR)
value
136 (7.0) 136 (6.0) 0.034
117
114
0.3
(50.0)
(44.0)
38 (7.8) 39 (6.5) <0.001
30 (32.0) 22 (21.5) <0.001
23.8 (6.2) 23 (6.0) 0.492
0.22
0.73
0.026
(0.94)
(4.39)
Pn (%)
value
20 (1)
9 (3)
0.03
11 (1)
15 (5) <0.001
857 (53) 166 (58) 0.095

3. Laboratory Findings
Comparison of laboratory values are shown in Table 3. Largest
difference between the two groups was observed in the blood
urea nitrogen (BUN), with bacterial pneumonia having a higher
BUN value compared to that found in viral pneumonia (30 [IQR:
32] vs. 22 [IQR: 21.5] mg/dL; P < 0.001). Serum procalcitonin
was only enumerated for 18 (6%) patients with CAVP and
118 (7%) patients with CABP; among those patients, serum
procalcitonin was significantly higher for CABP compared to
CAVP (0.73 [IQR: 4.39] vs. 0.22 [IQR: 0.94] µg/L; p = 0.026).
Other differences were clinically or statistically non-significant.
4. Radiological Features
Radiological findings are shown in Table 3. On chest
radiograph, patients with CAVP had more often diffuse bilateral
infiltrate (3% vs 1%; P = 0.03) and unilateral diffuse infiltrate
(5% vs 1%; P < 0.001). Multilobar infiltrates were also seen
more commonly, though statistically non-significant, in CAVP
than CABP (58% vs. 53%, P = 0.095).
5. Severity of Illness
Severity of disease on admission was characterized by frequency
of pneumonia severity index (PSI) class IV or greater, need
for ICU admission, altered mental status, need for ventilator
support, and need for vasopressors, as shown in Table 4. There
was a greater frequency of PSI ≥ class IV in CABP patients than

CAVP patients (38% vs. 30%; P = 0.014). Patients with CAVP
more frequently needed intensive care admission (33% vs. 17%;
P < 0.001), ventilator support (33% vs. 18%; P <0.001), and
vasopressors (20% vs. 9%; P <0.001). Altered mental status
was observed to have equal frequency in both groups (15%; P
= 0.928).
6. Patient outcomes
Patient outcomes were characterized by time to clinical stability,
hospital length of stay, in-hospital mortality, and 30-day
mortality, as shown in Table 4. Times to clinical stability was
not significantly different between CAVP and CABP groups (4
[IQR: 6] vs. 5 [IQR: 5] days); P = 0.276). Lengths of stay were 8
days in both groups. The percentage of in hospital mortality was
significantly higher in patients suffering from CAVP compared
to CABP (17% vs. 9%; P <0.001); however, mortality at 30
days was not found to be significantly higher (24% vs. 21%; P
= 0.345).

Discussion
Using the international CAPO database, we were able to
retrospectively evaluate 1,913 patients admitted to the hospital
for CAP to compare and contrast the clinical presentation,
morbidity, and mortality of CAVP and CABP. Demographically,
when compared to viral CAP, we found that bacterial etiologies
are more commonly found in males and older patients. Bacterial
pneumonia also is more frequent than viral pneumonia in
patients with chronic obstructive pulmonary disease, congestive
heart failure, human immunodeficiency virus, stroke, neoplastic
disease, and those on home oxygen. Physical exam characteristics
were found to be clinically non-significant between both groups.
Furthermore, the blood urea nitrogen level, a nonspecific
marker of plasma volume status, and frequency of PSI scores
≥4 were found to be higher in patients with CABP. However,
the overlapping similarity in findings when comparing physical
exam, laboratory data, and radiographic findings is in line with
the extreme difficulty in diagnosing between bacterial vs. viral
pneumonias. This is important to address as CAVP patients were
observed to have a greater frequency of overall disease severity
when comparing the frequency of need for ICU admission,
ventilator support, vasopressor therapy, and mortality.
Table 4 Severity of illness and clinical outcomes

Total Study Population
Severity of Disease on
Admission
Pneumonia severity index
risk class IV or V
Need for intensive care
Altered mental status
Need for ventilatory
support
Need for vasopressors
Outcomes
Time to Clinical Stability,
Median (IQR)
Length of Stay, Median
(IQR)

Bacterial
Infection
1627

Viral
Infection
286

Frequency (%)

P-value

620 (38)

87 (30)

0.014

282 (17)
243 (15)

94 (33)
41 (15)

<0.001
0.928

131 (18)

91 (33)

<0.001

65 (9)

55 (20)

<0.001
P-value

5 (5)

4 (6)

0.276

8 (9)

8 (11)

0.195

In-Hospital Mortality, n (%)

148 (9)

50 (17)

<0.001

Mortality at 30 Days, n (%)

248 (21)

47 (24)

0.345
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Our findings are both supported and refuted by currently
established literature, reiterating the ambiguity between and
difficulty in distinguishing the clinical presentation and severity
of illness of bacterial vs. viral etiologies of CAP. For example,
Johnstone found that viral pneumonias, in comparison to nonviral causes of pneumonia, were found to be more prevalent in
older and frailer patients [16]. Other studies have identified a
similar age difference between the two groups [6,17]. This is
contrary to our finding that CABP patients are older than CAVP
patients. Also, patients with COPD, CHF, and cerebrovascular
disease were also found to be more commonly affected by viral
CAP than bacterial CAP [17]. Similar to our findings, on the
other hand, malignancy was observed to be more commonly
found in patients with bacterial etiologies than viral [17]. HIV
was also observed to be more common in bacterial CAP than
viral CAP [18]. Despite these findings, it is important to also
note that multiple studies found no significant difference in age
or comorbidities between bacterial and viral etiologies of CAP
[19-22].
Medical literature also supports our findings that physical exam
and laboratory values are often unable to definitively distinguish
between bacterial vs. viral pneumonias [17]. We did not find
drastic differences between the two groups when comparing
physical exam findings. These minor, yet significant differences
were seen when comparing respiratory rate, blood pressure, and
degree of tachycardia. We found higher BUN levels in patients
suffering from CABP compared to CAVP. Higher levels of BUN
have been shown to be associated with increased mortality
in patients with CAP [23,24], however there were no studies
found comparing BUN levels in CAVP vs. CABP. While we
observed a significant difference in serum procalcitonin, the
large proportion of patients missing those values should cause
caution when interpreting these results. Though we observed
significant, yet minor differences in serum glucose, hematocrit,
and bicarbonate values between CABP and CAVP, Johnstone
went on to state, “it seems unlikely that any constellation of
symptoms, signs, and routine laboratory findings will ever
reliably differentiate between the presence or absence of a
virus.16 Furthermore, though there are several studies showing
the clinical and laboratory findings of pure bacterial, pure
viral, and combined bacterial-viral CAP infections [16,20,25],
diagnosing and differentiating purely viral from bacterial CAP
remains a problem as the etiology for a significant proportion
of CAP remains unknown. It is estimated that 40-60% of CAP
remains unidentified [3,26,27]. Caglayan states that bacterial
CAP infections resemble combined bacterial-viral CAP in terms
of mean age, immune status, leukocyte count, C-reactive protein
(CRP) values, hospitalization duration and CURB-65 score [25].
We also evaluated disease severity in the setting of purely viral
vs. purely bacterial CAP. CABP more frequently had PSI ≥ class
IV, however CAVP significantly showed higher frequencies of
ICU admission, intubation, vasopressor support, and in hospital
mortality. Though it has been previously demonstrated that PSI
≥ class IV indicates increased disease severity and is strongly
associated with ICU admission [28,29], our results show that
PSI scores cannot be used to accurately prognosticate viral CAPs.
Furthermore, literature suggests that PSI often underestimates
the risk of patients with Influenza A H1N1 pneumonia [30,31]
and neither PSI nor CURB-65 scores can be used to predict
ICU admission or need for mechanical ventilation in influenza
patients31. The CDC recommends early antiviral therapy for
patients who are suspected of suffering from influenza [32].
There exist limitations to our study. First, this was a retrospective

study. Secondly, while the multicenter and international nature
of the study increases the strength and generalizability of
results, the data collection and other differences in process of
care provide an unmeasurable confounding element that may
have significant impact on data collection. Also, a large portion
of patients included were afflicted by the H1N1 pandemic in
2009, that may explain the increased mortality for CAVP.
Patients affected by H1N1 are observed to be younger in age
and with fewer comorbidities [33]. Furthermore, pathogens
identified from respiratory samples may represent colonization
or active infection.
In conclusion, our study confirms the extreme difficulty
differentiating CABP from CAVP using demographics, physical
exam, or x-ray findings. We found no major clinical or laboratory
findings distinguishing CABP from CAVP. The increased
severity of illness of CAVP compared to bacterial etiologies
shows that PSI scores may not be an accurate indicator of
severity of disease. More studies are needed to identify the best
process of care for patients with CAP, including the potential
benefits of routine respiratory viral panel testing and empiric
antiviral therapy.
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